15.66
-0.57%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rallybio
From its filings with the US Securities and Exchange Commission
Rallybio is based in New Haven, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RLYB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $858,000 and a net loss of $9.0m. At that date it held total assets of $62.3m and shareholders' equity of $58.0m.
We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is a differentiated complement component 5 (“C5”) inhibitor with the potential to treat diseases of complement dysregulation. In addition, RLYB332, a long-acting matriptase-2 ("MTP-2") antibody for the treatment of diseases of iron overload, is currently in preclinical development.
On March 1, 2026, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Candid, a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio (the “Merger”). The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jul 2021
- Employees
- 44
- Website
- rallybio.com ↗
- Head office
- 234 CHURCH STREET, NEW HAVEN, CT, 06510
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Stephen UdenPresident, Chief Executive Officer, Director, since 2018$1.1m
- Mr. Jonathan LieberChief Financial Officer, Treasurer$839,216
- Dr. Steven RyderChief Medical Officer$911,061
- Ms. Helen BoudreauIndependent Director$78,981
- Dr. Wendy ChungIndependent Director$67,981
- Dr. Robert HopfnerIndependent Director$75,481
- Mr. Ronald HuntIndependent Director$75,481
- Dr. Lucian IancoviciIndependent Director$47,500
- Dr. Hui LiuIndependent Director$71,481
- Ms. Christine NashIndependent Director$68,981
- Ms. Paula SoteropoulosIndependent Director$70,000
- Ms. Samantha TracyInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 53
- Social
- 99
- Governance
- 32
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rallybio Corp's RLYB212 targets FNAIT prevention with a human monoclonal antibody.
- RLYB116 addresses complement dysregulation in PNH and gMG with a C5 inhibitor.
- The company's pipeline includes five advanced biotechnology programs for rare diseases.
Weaknesses
- Rallybio Corp has only 44 employees, indicating limited operational capacity.
- The company's IPO was in 2021, showing a relatively new market presence.
- Rallybio Corp's product candidates are still in development stages.
Opportunities
- Rallybio Corp's FNAIT program targets a rare hematological disease with unmet medical needs.
- RLYB116's C5 inhibitor application could expand to treat additional complement dysregulation conditions.
- The company's pipeline offers potential for multiple rare disease therapies in development.
Threats
- Rallybio Corp faces competition in the biotechnology sector for rare disease treatments.
- The company's reliance on a few product candidates creates development risk.
- Regulatory approval timelines for biotechnology therapies can cause delays.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.